WO2004009028A3 - Method and composition for treating and preventing influenza infection and symptoms thereof - Google Patents

Method and composition for treating and preventing influenza infection and symptoms thereof Download PDF

Info

Publication number
WO2004009028A3
WO2004009028A3 PCT/US2003/022836 US0322836W WO2004009028A3 WO 2004009028 A3 WO2004009028 A3 WO 2004009028A3 US 0322836 W US0322836 W US 0322836W WO 2004009028 A3 WO2004009028 A3 WO 2004009028A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
symptoms
composition
influenza infection
patient
Prior art date
Application number
PCT/US2003/022836
Other languages
French (fr)
Other versions
WO2004009028A2 (en
Inventor
Scott Morham
Kenton Zavitz
Adrian Hobden
Original Assignee
Myriad Genetics Inc
Scott Morham
Kenton Zavitz
Adrian Hobden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc, Scott Morham, Kenton Zavitz, Adrian Hobden filed Critical Myriad Genetics Inc
Priority to AU2003259198A priority Critical patent/AU2003259198A1/en
Publication of WO2004009028A2 publication Critical patent/WO2004009028A2/en
Publication of WO2004009028A3 publication Critical patent/WO2004009028A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods for preventing and treating influenza infection and symtoms thereof by introducing cells displaying an influenza altered budding phenotype into a patient, or by administering to a patient nucleic acids, polypeptides and small organic compounds to cause the formation of cells displaying influenza altered budding phenotype in the body of the patient.
PCT/US2003/022836 2002-07-19 2003-07-21 Method and composition for treating and preventing influenza infection and symptoms thereof WO2004009028A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003259198A AU2003259198A1 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing influenza infection and symptoms thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39733902P 2002-07-19 2002-07-19
US60/397,339 2002-07-19
US45300403P 2003-03-07 2003-03-07
US60/453,004 2003-03-07

Publications (2)

Publication Number Publication Date
WO2004009028A2 WO2004009028A2 (en) 2004-01-29
WO2004009028A3 true WO2004009028A3 (en) 2005-02-17

Family

ID=30773014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/022836 WO2004009028A2 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing influenza infection and symptoms thereof

Country Status (2)

Country Link
AU (1) AU2003259198A1 (en)
WO (1) WO2004009028A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070108371A (en) * 2005-01-05 2007-11-09 필라델피아 헬스 앤드 에듀케이션 코퍼레이션 Delivery vehicles, bioactive substances and viral vaccines
EP2080768A1 (en) * 2008-01-21 2009-07-22 Freie Universität Berlin Method for studying virus particle release
WO2011088451A1 (en) * 2010-01-15 2011-07-21 Novavax, Inc. Uses of influenza virus-like particles (vlps) for characterization of neuraminidase and hemagglutinin activity
EP3543698A1 (en) * 2018-03-20 2019-09-25 Helmholtz-Zentrum für Infektionsforschung GmbH Method for determining vaccine efficacy in an individual and means therefore

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALI A. ET AL.: "Influenza virus assembly: Effect of influenza virus glycoproteins on the membrane association of M1 protein", JOURNAL OF VIROLOGY, vol. 74, no. 18, 2000, pages 8709 - 8719, XP002982630 *
GOMEZ-PUERTAS ET AL.: "Influenza virus matrix protein is the major driving force in virus budding", JOURNAL OF VIROLOGY, vol. 74, no. 24, 2000, pages 11538 - 11547, XP002196048 *

Also Published As

Publication number Publication date
AU2003259198A8 (en) 2004-02-09
WO2004009028A2 (en) 2004-01-29
AU2003259198A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
WO2005027966A3 (en) Antibodies with altered effector functions
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2006124012A3 (en) Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
NO20055766L (en) Positive modulators of nicotine acetylcholine receptors
WO2003096977A3 (en) Methods of treating hepatitis
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2001023421A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2006041409A8 (en) Medical solution, method for producing and use thereof
WO2002091858A8 (en) Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
UA86399C2 (en) Normal;heading 1;heading 2;USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF ANGIODEPENDENT DISEASES
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2004043379A3 (en) Chemical compounds
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
WO2003102185A3 (en) Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2003059262A3 (en) Method and composition for treating and preventing hiv infection and aids
WO2004009028A3 (en) Method and composition for treating and preventing influenza infection and symptoms thereof
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2004009032A3 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof
WO2004016738A3 (en) Method and composition for treating and preventing hepatitis c infection
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP